Increased risk of cognitive and functional decline in patients with atrial fibrillation: Results of the ONTARGET and TRANSCEND studies

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 6, 2012, Pages

  Marzona, Irene ^a,b   O'Donnell, Martin ^a,c   Teo, Koon ^a   Gao, Peggy ^a   Anderson, Craig ^d   Bosch, Jackie ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; PLACEBO; RAMIPRIL PLUS TELMISARTAN; TELMISARTAN; UNCLASSIFIED DRUG;

AGED; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH CARE FACILITY; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PHYSICAL DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STROKE;

EID: 84859531891     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.111173     Document Type: Article

References (28)

1. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001;119:194S-206S. (Pubitemid 32154200)
2. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007;6:611-9. (Pubitemid 46921055)
3. Mead GE, Keir S. Association between cognitive impairment and atrial fibrillation: a systematic review. J Stroke Cerebrovasc Dis 2001;10:35-43. (Pubitemid 32489092)
4. Knecht S, Oelschläger C, Duning T et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125-32.
5. Miyasaka Y, Barnes ME, Petersen RC, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 2007;28:1962-7. (Pubitemid 47579533)
6. Rastas S, Verkkoniemi A, Polvikoski T, et al. Atrial fibrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older. Stroke 2007;38:1454-60. (Pubitemid 46684144)
7. Forti P, Maioli F, Pisacane N, et al. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment (MCI). Arch Gerontol Geriatr 2007;44(Suppl 1):155-65.
8. Forti P, Maioli F, Pisacane N, et al. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment. Neurol Res 2006;28:625-9. (Pubitemid 44433321)
9. Sabatini T, Frisoni GB, Barbisoni P, et al. Atrial fibrillation and cognitive disorders in older people. J Am Geriatr Soc 2000; 48:387-90. (Pubitemid 30207762)
10. Rozzini R, Sabatini T, Trabucchi M. Chronic atrial fibrillation and low cognitive function. Stroke 1999;30:190-1. (Pubitemid 29029466)
11. Ott A, Breteler MM, de Bruyne MC. van HF, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316-21.
12. O'Connell JE, Gray CS. Atrial fibrillation and cognitive impairment. Lancet 1992;340:1169.
13. Park H, Hildreth A, Thomson R, et al. Non-valvular atrial fibrillation and cognitive decline: a longitudinal cohort study. Age Ageing 2007;36:157-63. (Pubitemid 46455394)
14. Bilato C, Corti MC, Baggio G, et al. Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study). Am J Cardiol 2009;104:1092-7.
15. Kwok CS, Loke YK, Hale R, et al. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology 2011;76:914-22.
16. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.
17. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-59. (Pubitemid 351522739)
18. Hensel A, Luck T, Luppa M, et al. Does a reliable decline in Mini-Mental State Examination total score predict dementia? Diagnostic accuracy of two reliable change indices. Dement Geriatr Cogn Disord 2009;27:50-8.
19. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069-75. (Pubitemid 36548935)
20. Anstey KJ, Burns RA, Birrell CL, et al. Estimates of probable dementia prevalence from population-based surveys compared with dementia prevalence estimates based on meta-analyses. BMC Neurol 2010;10:62.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
22. Black SE. Vascular cognitive impairment: epidemiology, subtypes, diagnosis and management. J R Coll Physicians Edinb 2011;41:49-56.
23. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666.
24. Hajjar I, Quach L, Yang F, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation 2011; 123:858-65.
25. Murray ME, Senjem ML, Petersen RC, et al. Functional impact of white matter hyperintensities in cognitively normal elderly subjects. Arch Neurol 2010;67:1379-85.
26. Rektor I, Rektorova I, Kubova D. Vascular parkinsonism - an update. J Neurol Sci 2006;248:185-91. (Pubitemid 44647302)
27. Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159: 348-53.
28. Kasten M, Bruggemann N, Schmidt A, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2010;75:478-9.